Antineoplastic Agents, Immunological

"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.

Descriptor ID	D000074322
MeSH Number(s)	D27.505.954.248.384
Concept/Terms	Antineoplastic Agents, Immunological Antineoplastic Agents, Immunological Immunological Antineoplastic Agents Antineoplastics, Monoclonal Antibodies Antineoplastics, Monoclonal Antibodies Antibodies Antineoplastics, Monoclonal Monoclonal Antibodies Antineoplastics Monoclonal Antibodies, Antineoplastic Antineoplastic Monoclonal Antibodies Antineoplastic MAbs Antineoplastics, Monoclonal Antibody Monoclonal Antibody Antineoplastics MAbs, Antineoplastic

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Immunological [D27.505.954.248.384]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Immunological".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.

Bar chart showing 34 publications over 8 distinct years, with a maximum of 9 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2016	1	0	1
2017	5	2	7
2018	5	2	7
2019	6	3	9
2020	2	1	3
2021	3	1	4
2022	2	0	2
2024	0	1	1

Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.

Vlachou E, Mamtani R, Hahn NM, Iii BJ, Hoffman-Censits J, Nimgaonkar V. Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin. Clin Genitourin Cancer. 2024 Jun; 22(3):102090.

View in: PubMed
Harel M, Lahav C, Jacob E, Dahan N, Sela I, Elon Y, Raveh Shoval S, Yahalom G, Kamer I, Zer A, Sharon O, Carbone DP, Dicker AP, Bar J, Shaked Y. Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. J Immunother Cancer. 2022 Jun; 10(6).

View in: PubMed
Cohen F, Yuan H, Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. BioDrugs. 2022 May; 36(3):341-358.

View in: PubMed
Ghosh A, Harish Bindiganavile S, Bhat N, Lee AG. A Case of Miller Fisher Syndrome Due to the Use of Cemiplimab. J Neuroophthalmol. 2021 Sep 01; 41(3):e343-e345.

View in: PubMed
Karadag AS, Wang JV, Parish LC. Monoclonal Antibodies: Magic Bullets Since 1975. Skinmed. 2021; 19(4):249-251.

View in: PubMed
Liu X, Adorno-Cruz V, Chang YF, Jia Y, Kawaguchi M, Dashzeveg NK, Taftaf R, Ramos EK, Schuster EJ, El-Shennawy L, Patel D, Zhang Y, Cristofanilli M, Liu H. EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer. Theranostics. 2021; 11(13):6632-6643.

View in: PubMed
MacFarlane AW, Yeung HM, Alpaugh RK, Dulaimi E, Engstrom PF, Dasari A, Campbell KS, Vijayvergia N. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunol Immunother. 2021 Jul; 70(7):1893-1906.

View in: PubMed
Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B, Mamtani R. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Clin Genitourin Cancer. 2021 02; 19(1):e17-e30.

View in: PubMed
Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 10 15; 147(8):2190-2198.

View in: PubMed
Ghouse SM, Vadrevu SK, Manne S, Reese B, Patel J, Patel B, Silwal A, Lodhi N, Paterson Y, Srivastava SK, Karbowniczek M, Markiewski MM. Therapeutic Targeting of Vasculature in the Premetastatic and Metastatic Niches Reduces Lung Metastasis. J Immunol. 2020 02 15; 204(4):990-1000.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement